CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will be
hosting a webinar to provide an overview of how LINZESS will be
reflected in Ironwood's quarterly income statements following its
commercial availability in the U.S. Ironwood will co-commercialize the
product in the U.S. through its collaboration with Forest Laboratories,
Inc.
The webinar will take place on Tuesday, November 6, 2012 at 12:00 p.m.
Eastern Time. Individuals interested in participating in the webinar
should visit the Investors section of Ironwood's website at www.ironwoodpharma.com;
please log on at least 15 minutes prior to the start of the event to
ensure adequate time for any software downloads that may be required.
For listen-only participation, the webinar can also be accessed by
dialing (866) 437-1772 (U.S. and Canada) or (973) 638-3229
(international) and use the conference ID number 45259150.
A replay of the webinar will be available on Ironwood's website or via
telephone starting November 6, 2012 at approximately 3:00 p.m. Eastern
Time, running through 11:59 p.m. Eastern Time on November 13, 2012. To
listen to the replay by phone, dial (855) 859-2056 (U.S. and Canada) or
(404) 537-3406 (international) and use conference ID number 45259150.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial
pharmaceutical company dedicated to the art and science of great
drugmaking. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.
Ironwood Pharmaceuticals, Inc.
Media Relations
Lisa
Buffington, 617-374-5103
Vice President, Corporate Communications
lbuffington@ironwoodpharma.com
or
Investor
Relations
Meredith Kaya, 617-374-5082
Associate Director,
Investor Relations
mkaya@ironwoodpharma.com
Source: Ironwood Pharmaceuticals, Inc.
News Provided by Acquire Media